Randomized phase III trial: Topotecan vs. topotecan/etoposide vs topotecan/gemcitabine as second-line treatment for patients with relapsed ovarian cancer.

被引：0
|
作者：
Sehouli, J
Sommer, H
Klare, P
Stauch, M
Zeimet, A
Paulenz, A
Renziehausen, K
Keil, E
Lichtenegger, W
Oskay-Ozcelik, G
机构：
[1] Med Univ, Charite, Berlin, Germany
[2] NE German Soc Gynecol Oncol, Berlin, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5139
引用
收藏
页码：483S / 483S
页数：1
相关论文
共 50 条
  • [21] A Phase II Clinical Trial of Topotecan in Japanese Patients with Relapsed Ovarian Carcinoma
    Aoki, Daisuke
    Katsumata, Noriyuki
    Nakanishi, Toru
    Kigawa, Junzo
    Fujiwara, Keiichi
    Takehara, Kazuhiro
    Kamiura, Shoji
    Hiura, Masamichi
    Hatae, Masayuki
    Sugiyama, Toru
    Ochiai, Kazunori
    Noda, Kiichiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (03) : 320 - 327
  • [22] Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer
    N C Levitt
    D J Propper
    S Madhusudan
    J P Braybrooke
    C Echeta
    R te Poele
    S L Davies
    E Flanagan
    I D Hickson
    S Joel
    T S Ganesan
    British Journal of Cancer, 2005, 93 : 60 - 69
  • [23] Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer
    Edelman, Martin J.
    Dvorkin, Mikhail
    Laktionov, Konstatin
    Navarro, Alejandro
    Juan-Vidal, Oscar
    Kozlov, Vadim
    Golden, Gil
    Jordan, Odette
    Deng, C. Q.
    Bentsion, Dmitriy
    Chouaid, Christos
    Dechev, Hristo
    Dowlati, Afshin
    Fernandez Nunez, Natalia
    Ivashchuk, Olexandr
    Kiladze, Ivane
    Kortua, Tsira
    Leighl, Natasha
    Luft, Aleksandr
    Makharadze, Tamta
    Min, YoungJoo
    Quantin, Xavier
    LUNG CANCER, 2022, 166 : 135 - 142
  • [24] Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer
    Levitt, NC
    Propper, DJ
    Madhusudan, S
    Braybrooke, JP
    Echeta, C
    Poele, RT
    Davies, SL
    Flanagan, E
    Hickson, ID
    Joel, S
    Ganesan, TS
    BRITISH JOURNAL OF CANCER, 2005, 93 (01) : 60 - 69
  • [25] Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study
    Creemers, GJ
    Bolis, G
    Gore, M
    Scarfone, G
    Lacave, AJ
    Guastalla, JP
    Despax, R
    Favalli, G
    Kreinberg, R
    VanBelle, S
    Hudson, I
    Verweij, J
    Huinink, WWT
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (12) : 3056 - 3061
  • [26] A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer
    Jones, Suzanne
    Thompson, Dana
    Barton, John
    Patton, Jeff
    Shipley, Dianna
    Greco, E. Anthony
    Spigel, David
    Infante, Jeff
    Burris, Howard A., III
    CLINICAL LUNG CANCER, 2008, 9 (03) : 154 - 159
  • [27] Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma -: Results of a phase 2 trial
    Simon, Thorsten
    Langler, Ared
    Berthold, Frank
    Klingebiel, Thomas
    Hero, Barbara
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2007, 29 (02) : 101 - 106
  • [28] The role of topotecan in treating small cell lung cancer: second-line treatment
    von Pawel, J
    LUNG CANCER, 2003, 41 : S3 - S8
  • [29] Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial
    Paz-Ares, L.
    Ciuleanu, T.
    Navarro, A.
    Fulop, A.
    Cousin, S.
    Bonanno, L.
    Smit, E.
    Chiappori, A.
    Olmedo, M. E.
    Horvath, I.
    Grohe, C.
    Lopez-Vilarino, J. A.
    Nunez, R.
    Nieto, A.
    Cullell, M.
    Vasco, N.
    Kahatt, C.
    Zeaiter, A.
    Carcereny, E.
    Roubec, J.
    Syrigos, K.
    Lo, G.
    Barneto, I.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S844 - S845
  • [30] Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial
    Baize, Nathalie
    Monnet, Isabelle
    Greillier, Laurent
    Geier, Margaux
    Lena, Herve
    Janicot, Henri
    Vergnenegre, Alain
    Crequit, Jacky
    Lamy, Regine
    Auliac, Jean-Bernard
    Letreut, Jacques
    Le Caer, Herve
    Gervais, Radj
    Dansin, Eric
    Madroszyk, Anne
    Renault, Patrick-Aldo
    Le Garff, Gwenaelle
    Falchero, Lionel
    Berard, Henri
    Schott, Roland
    Saulnier, Patrick
    Chouaid, Christos
    LANCET ONCOLOGY, 2020, 21 (09): : 1224 - 1233
12345